Lantibiotic Production via Reduced WPC and Protease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing lantibiotics result in high levels of whey protein concentrate (WPC)-related impurities, limiting their utility for pharmaceutical applications due to insufficient purity and efficiency.
Innovation Solution
Culturing lantibiotic-producing microorganisms in a medium with reduced WPC concentrations and subjecting it to high shear conditions, combined with protease treatment to selectively remove impurities, yields pharmaceutical-grade lantibiotics free from WPC-derived contaminants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods using high concentrations of whey protein concentrate (WPC) are used for lantibiotic production, then production efficiency is improved, but purity deteriorates due to high levels of WPC-related impurities
Solution Approach 1:
The patent changes the concentration parameter of WPC in the culture medium from high levels (conventional) to reduced levels (5-20 g/L), which fundamentally alters the impurity profile. This parameter change allows maintaining production efficiency while significantly reducing WPC-related impurities such as α-lactalbumin and β-lactoglobulin oligomers, thereby resolving the contradiction between productivity and manufacturing precision
Solution Approach 2:
The patent extracts and removes WPC-related impurities from the fermentation broth through purification steps. By specifically targeting and removing these impurities that co-produce with lantibiotics under conventional high WPC conditions, the method achieves high purity pharmaceutical-grade lantibiotics while maintaining efficient production
2Quantity of substance
If high concentrations of WPC are used in culture media, then lantibiotic yield is improved, but impurity levels increase making pharmaceutical application impossible
Solution Approach 1:
The patent applies parameter changes by reducing WPC concentration in the culture medium to 5-20 g/L, which fundamentally alters the metabolic behavior of lantibiotic-producing microorganisms. This change maintains sufficient lantibiotic yield while dramatically reducing the generation of harmful WPC-related impurities, enabling pharmaceutical applications
Solution Approach 2:
The patent converts the harmful effect of WPC (which generates impurities at high concentrations) into a benefit by using optimized, reduced concentrations. This allows WPC to continue serving as an effective nitrogen and carbon source for microbial growth and lantibiotic production, while eliminating the harmful impurity generation that prevented pharmaceutical use
3Ease of manufacture
If conventional production methods are used, then cost-effectiveness is maintained, but pharmaceutical-grade purity cannot be achieved
Solution Approach 1:
The patent changes the WPC concentration parameter to optimized levels (5-20 g/L) that simultaneously achieve cost-effectiveness and pharmaceutical-grade purity. This parameter optimization eliminates the need for expensive additional purification steps while meeting pharmaceutical requirements, thereby resolving the contradiction between ease of manufacture and manufacturing precision
Solution Approach 2:
The patent applies preliminary action by optimizing the culture medium composition before fermentation begins. By pre-setting the WPC concentration at optimal levels and using appropriate protease treatments, the method prevents excessive impurity formation from the start, making the subsequent purification process simpler and more cost-effective while achieving pharmaceutical-grade purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach produces lantibiotics with high purity and reduced impurities, maintaining yield comparable to conventional methods, and achieving pharmaceutical-grade quality by minimizing α-lactalbumin and β-lactoglobulin oligomers and aggregates.
Implementation Method 1
protease treatment to selectively remove impurities
Implementation Method 2
subjecting it to high shear conditions
Data Source
AI summary
Methods and systems for efficient and cost-effective production of lantibiotics. The methods and systems are capable of producing lantibiotics having high purity suitable for pharmaceutical use.